Edgestream Partners L.P. bought a new position in shares of Progyny, Inc. (NASDAQ:PGNY – Free Report) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund bought 51,861 shares of the company’s stock, valued at approximately $1,306,000. Edgestream Partners L.P. owned about 0.07% of Progyny at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also modified their holdings of the stock. Public Employees Retirement System of Ohio bought a new position in shares of Progyny during the second quarter worth approximately $29,000. Nykredit A S bought a new stake in Progyny in the 2nd quarter valued at about $38,000. IFP Advisors Inc increased its stake in Progyny by 376.0% during the 2nd quarter. IFP Advisors Inc now owns 1,961 shares of the company’s stock worth $57,000 after acquiring an additional 1,549 shares during the period. Toth Financial Advisory Corp bought a new position in shares of Progyny in the second quarter worth $65,000. Finally, Integrated Wealth Concepts LLC acquired a new position in Progyny in the second quarter valued at about $74,000. Institutional investors own 94.93% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of analysts have recently weighed in on the stock. Wall Street Zen raised shares of Progyny from a “buy” rating to a “strong-buy” rating in a report on Sunday, November 8th. Truist Financial reissued a “buy” rating and set a $42.00 price target (up from $36.00) on shares of Progyny in a report on Tuesday, November 17th. Zacks Research raised shares of Progyny from a “hold” rating to a “strong-buy” rating in a research note on Wednesday. JPMorgan Chase & Co. upped their price target on shares of Progyny from $30.00 to $35.00 and gave the stock a “neutral” rating in a report on Monday, November 9th. Finally, Jefferies Financial Group set a $33.00 price target on Progyny in a research note on Tuesday, September 8th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $35.83.
Insider Buying and Selling
In other Progyny news, insider Geoffrey Clapp sold 774 shares of the business’s stock in a transaction that occurred on Wednesday, November 11th. The stock was sold at an average price of $36.41, for a total transaction of $28,181.34. Following the completion of the sale, the insider directly owned 58,235 shares of the company’s stock, valued at approximately $2,120,336.35. The trade was a 1.31% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Chairman David J. Schlanger sold 35,392 shares of the stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $35.36, for a total value of $1,251,461.12. Following the completion of the sale, the chairman directly owned 238,462 shares of the company’s stock, valued at $8,432,016.32. The trade was a 12.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 630,072 shares of company stock worth $22,363,084 over the last ninety days. Insiders own 9.90% of the company’s stock.
Progyny Stock Up 0.7%
Shares of PGNY stock opened at $35.71 on Friday. The firm has a 50 day moving average of $29.41 and a 200-day moving average of $25.18. Progyny, Inc. has a 52 week low of $16.10 and a 52 week high of $37.21. The company has a market cap of $2.63 billion, a price-to-earnings ratio of 32.76, a price-to-earnings-growth ratio of 1.64 and a beta of 0.97.
Progyny (NASDAQ:PGNY – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.21. Progyny had a net margin of 6.80% and a return on equity of 19.82%. The company had revenue of $341.25 million for the quarter, compared to analysts’ expectations of $340.76 million. During the same quarter in the prior year, the firm earned $0.15 EPS. The business’s revenue was up 8.9% on a year-over-year basis. Analysts anticipate that Progyny, Inc. will post 1.43 earnings per share for the current year.
Progyny Profile
Progyny, Inc. provides fertility and family-building benefits to employers and their employees. Its services are designed to help members navigate care options, access fertility specialists and receive support throughout treatment. The company’s offerings include coverage for treatments such as in vitro fertilization and egg freezing, along with fertility medications through its pharmacy benefit. Progyny also supports other family-building paths, including adoption and surrogacy, depending on the plan selected by an employer.
Further Reading
- Five stocks we like better than Progyny
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.
